Examkin

Soru

Zorluk: KolayGynecologic Oncology

Match each genetic syndrome or environmental exposure with the gynecologic malignancy for which it carries the highest risk.

  • Lynch syndromeEndometrial and ovarian carcinomas
  • BRCA1 mutationHigh-grade serous ovarian and fallopian tube carcinomas
  • In utero diethylstilbestrol (DES) exposureClear cell adenocarcinoma of the vagina and cervix
  • Persistent high-risk HPV (types 16 and 18) infectionSquamous cell carcinoma of the cervix, vagina, and vulva

Cevap

Lynch syndrome matches with Endometrial and ovarian carcinomas; BRCA1 mutation matches with High-grade serous ovarian and fallopian tube carcinomas; In utero DES exposure matches with Clear cell adenocarcinoma of the vagina and cervix; Persistent high-risk HPV matches with Squamous cell carcinoma of the cervix, vagina, and vulva.
Each exposure or genetic syndrome strongly predisposes patients to specific gynecologic malignancies. Lynch syndrome is associated with endometrial and ovarian cancers due to mismatch repair defects. BRCA1 mutations increase the risk for breast, ovarian, and fallopian tube cancers due to homologous recombination defects. DES exposure in utero disrupts Mullerian development, leading to clear cell adenocarcinoma of the vagina. Finally, high-risk HPV types 16 and 18 drive squamous epithelial transformation in the cervix, vagina, and vulva.

Adım Adım Çözüm

1
Identify the primary gynecologic cancers associated with mismatch repair gene mutations (Lynch syndrome).
Patients with Lynch syndrome are at a significantly increased risk for endometrial cancer and ovarian cancer.
Lynch syndrome is the most common inherited syndrome predisposing to endometrial cancer.
2
Recall the gynecologic malignancies linked to homologous recombination deficiency (BRCA1).
BRCA1 is strongly associated with hereditary breast and ovarian cancer syndrome, specifically high-grade serous carcinomas of the ovary and fallopian tubes.
BRCA1 mutations impair DNA double-strand break repair, leading to these specific malignancies.
3
Associate historical pharmacological exposures with specific structural and malignant outcomes.
DES exposure in utero is a highly specific, classic risk factor for vaginal and cervical clear cell adenocarcinoma.
DES was previously used to prevent miscarriage and affected the developing Mullerian tract in female fetuses.
4
Link viral oncogenesis to lower genital tract malignancies.
HPV 16 and 18 produce E6 and E7 oncoproteins that lead to cervical, vaginal, and vulvar squamous cell carcinomas.
HPV is the necessary cause for over 90% of cervical cancers and a large portion of vaginal and vulvar cancers.

Anahtar Kavram

Risk Factors and Genetic Syndromes in Gynecologic Oncology
Bu soruyu puanla

Konular

Gynecologic Oncology

Bu konudan daha fazla soru